Manufactures and sells healthcare products, including topical analgesics and women's health medicines. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $455.5M would still be left in the vault — a solid cushion for hard times.
The market pays 106.3× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 60% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $459.9M in the vault; even if every debt were paid off, $455.5M would remain.
It pays out $0.66 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 106 times its annual profit. Even a small disappointment could hit the price hard.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.